Novel staging for gastric neuroendocrine neoplasms by incorporating the WHO grading into the TNM staging system.
American joint committee on cancer
TNM
WHO grade
gastric neuroendocrine neoplasms
surveillance, epidemiology and end result
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
revised:
16
10
2022
received:
17
07
2022
accepted:
01
11
2022
medline:
5
4
2023
pubmed:
18
11
2022
entrez:
17
11
2022
Statut:
ppublish
Résumé
The 8th tumor-node-metastasis (TNM) classification of the American Joint Committee on Cancer (AJCC) can be used to estimate the prognosis of gastric neuroendocrine tumor (gNET) and gastric neuroendocrine carcinoma (gNEC) patients but not gastric neuroendocrine neoplasms (gNENs). First, in the SEER (training) dataset, a TNMG system was built by combining the WHO G grade (G1-4; NEC grouped into G4) with the 8th AJCC T (T1-4), N (N0-1), and M (M0-1) stage, which was then validated in a Chinese (validation) cohort. In all, 2245 gNENs cases from the training dataset and 280 cases from the validation dataset were eligible. The T stage, M stage, and G grade were independent prognostic factors for OS in both datasets (all p < 0.05). The TNMG staging system demonstrated better C-index for predicting OS than the 8th AJCC TNM staging system in both the training (0.87, 95%CI: 0.86-0.88 vs. 0.79, 95%CI: 0.77-0.81) and validation (0.77, 95%CI: 0.73-0.80 vs. 0.75, 95%CI: 0.71-0.79) datasets. The AUC of the 3-year OS for the TNMG staging system was 0.936 and 0.817 in the SEER and validation dataset, respectively; higher than those of the 8th AJCC system (vs. 0.843 and 0.779, respectively). DCA revealed that compared with the 8th AJCC TNM staging system, the TNMG staging system demonstrated superior net prognostic benefit in both the training and validation datasets. The proposed TNMG staging system could more accurately predict the 3- and 5-year OS rate of gNENs patients than the 8th AJCC TNM staging system.
Sections du résumé
BACKGROUND
The 8th tumor-node-metastasis (TNM) classification of the American Joint Committee on Cancer (AJCC) can be used to estimate the prognosis of gastric neuroendocrine tumor (gNET) and gastric neuroendocrine carcinoma (gNEC) patients but not gastric neuroendocrine neoplasms (gNENs).
METHODS
First, in the SEER (training) dataset, a TNMG system was built by combining the WHO G grade (G1-4; NEC grouped into G4) with the 8th AJCC T (T1-4), N (N0-1), and M (M0-1) stage, which was then validated in a Chinese (validation) cohort.
RESULTS
In all, 2245 gNENs cases from the training dataset and 280 cases from the validation dataset were eligible. The T stage, M stage, and G grade were independent prognostic factors for OS in both datasets (all p < 0.05). The TNMG staging system demonstrated better C-index for predicting OS than the 8th AJCC TNM staging system in both the training (0.87, 95%CI: 0.86-0.88 vs. 0.79, 95%CI: 0.77-0.81) and validation (0.77, 95%CI: 0.73-0.80 vs. 0.75, 95%CI: 0.71-0.79) datasets. The AUC of the 3-year OS for the TNMG staging system was 0.936 and 0.817 in the SEER and validation dataset, respectively; higher than those of the 8th AJCC system (vs. 0.843 and 0.779, respectively). DCA revealed that compared with the 8th AJCC TNM staging system, the TNMG staging system demonstrated superior net prognostic benefit in both the training and validation datasets.
CONCLUSIONS
The proposed TNMG staging system could more accurately predict the 3- and 5-year OS rate of gNENs patients than the 8th AJCC TNM staging system.
Identifiants
pubmed: 36394081
doi: 10.1002/cam4.5437
pmc: PMC10067116
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
6623-6636Informations de copyright
© 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Cives M, Strosberg JR. Gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin. 2018;68(6):471-487.
Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063-3072.
Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335-1342.
Pan C, Wu J, Zheng S, et al. Depression accelerates gastric cancer invasion and metastasis by inducing a neuroendocrine phenotype via the catecholamine/beta2 -AR/MACC1 axis. Cancer Commun (Lond). 2021;41(10):1049-1070.
Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76(2):182-188.
Amin MB, Greene FL, Edge SB, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin. 2017;67(2):93-99.
Yang M, Zhang Y, Zeng L, et al. Survivals of patients with surgically treated and high-grade pancreatic neuroendocrine carcinomas: a comparative study between two American joint committee on cancer 8th tumor-node-metastasis staging systems. Eur J Surg Oncol. 2019;45(6):1054-1060.
Cho JH, Ryu JK, Song SY, et al. Prognostic validity of the American joint committee on cancer and the European neuroendocrine tumors staging classifications for pancreatic neuroendocrine tumors: a retrospective Nationwide multicenter study in South Korea. Pancreas. 2016;45(7):941-946.
Zhang XF, Xue F, Wu Z, et al. Development and validation of a modified eighth AJCC staging system for primary pancreatic neuroendocrine tumors. Ann Surg. 2022;275(6):e773-e780.
Wang H, Lin Z, Li G, et al. Validation and modification of staging Systems for Poorly Differentiated Pancreatic Neuroendocrine Carcinoma. BMC Cancer. 2020;20(1):188.
Hu P, Bai J, Liu M, et al. Trends of incidence and prognosis of gastric neuroendocrine neoplasms: a study based on SEER and our multicenter research. Gastric Cancer. 2020;23(4):591-599.
Lin J, Zhao Y, Zhou Y, et al. Which staging system is more suitable for gastric neuroendocrine cancer and mixed Adenoneuroendocrine carcinomas? A Multicenter Cohort Study. Neuroendocrinology. 2021;111(11):1130-1140.
Dias AR, Azevedo BC, Alban LBV, et al. Gastric neuroendocrine tumor: review and update. Arq Bras Cir Dig. 2017;30(2):150-154.
Wang M, Ding D, Qin T, et al. New staging classification for pancreatic neuroendocrine neoplasms combining TNM stage and WHO grade classification. Cancer Lett. 2021;518:207-213.
Lu J, Zhao YJ, Zhou Y, et al. Modified staging system for gastric neuroendocrine carcinoma based on American joint committee on cancer and European neuroendocrine tumor society systems. Br J Surg. 2020;107(3):248-257.
Luo G, Javed A, Strosberg JR, et al. Modified staging classification for pancreatic neuroendocrine tumors on the basis of the American joint committee on cancer and European neuroendocrine tumor society systems. J Clin Oncol. 2017;35(3):274-280.
Martin JA, Warner RR, Wisnivesky JP, Kim MK. Improving survival prognostication of gastroenteropancreatic neuroendocrine neoplasms: revised staging criteria. Eur J Cancer. 2017;76:197-204.
Fang C, Wang W, Feng X, et al. Nomogram individually predicts the overall survival of patients with gastroenteropancreatic neuroendocrine neoplasms. Br J Cancer. 2017;117(10):1544-1550.
Huang YC, Yang NN, Chen HC, et al. Clinicopathological features and prognostic factors associated with gastroenteropancreatic mixed neuroendocrine non-neuroendocrine neoplasms in Chinese patients. World J Gastroenterol. 2021;27(7):624-640.
Xie JW, Sun YQ, Feng CY, et al. Evaluation of clinicopathological factors related to the prognosis of gastric neuroendocrine carcinoma. Eur J Surg Oncol. 2016;42(10):1464-1470.
Carlsen EA, Fazio N, Granberg D, et al. Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study. Endocr Relat Cancer. 2019;26(2):227-239.
Khan MS, Luong TV, Watkins J, Toumpanakis C, Caplin ME, Meyer T. A comparison of Ki-67 and mitotic count as prognostic markers for metastatic pancreatic and midgut neuroendocrine neoplasms. Br J Cancer. 2013;108(9):1838-1845.
Martin-Perez E, Capdevila J, Castellano D, et al. Prognostic factors and long-term outcome of pancreatic neuroendocrine neoplasms: Ki-67 index shows a greater impact on survival than disease stage. The large experience of the Spanish National Tumor Registry (RGETNE). Neuroendocrinology. 2013;98(2):156-168.
Pusceddu S, Barretta F, Trama A, et al. A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors. Endocr Relat Cancer. 2018;25(6):607-618.
Martin RC, Kooby DA, Weber SM, et al. Analysis of 6,747 pancreatic neuroendocrine tumors for a proposed staging system. J Gastrointest Surg. 2011;15(1):175-183.
Panzuto F, Boninsegna L, Fazio N, et al. Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression. J Clin Oncol. 2011;29(17):2372-2377.
Yang M, Zeng L, Ke NW, et al. World Health Organization grading classification for pancreatic neuroendocrine neoplasms: a comprehensive analysis from a large Chinese institution. BMC Cancer. 2020;20(1):906.
Folkert IW, Sinnamon AJ, Concors SJ, et al. Grade is a dominant risk factor for metastasis in patients with rectal neuroendocrine tumors. Ann Surg Oncol. 2020;27(3):855-863.
Genc CG, Klumpen HJ, vanOijen MGH, vanEijck CHJ, Nieveen van Dijkum EJM. A Nationwide population-based study on the survival of patients with pancreatic neuroendocrine tumors in The Netherlands. World J Surg. 2018;42(2):490-497.
Keck KJ, Choi A, Maxwell JE, et al. Increased grade in neuroendocrine tumor metastases negatively impacts survival. Ann Surg Oncol. 2017;24(8):2206-2212.
Strosberg JR, Cheema A, Weber J, Han G, Coppola D, Kvols LK. Prognostic validity of a novel American joint committee on cancer staging classification for pancreatic neuroendocrine tumors. J Clin Oncol. 2011;29(22):3044-3049.
Tsolakis AV, Ragkousi A, Vujasinovic M, Kaltsas G, Daskalakis K. Gastric neuroendocrine neoplasms type 1: a systematic review and meta-analysis. World J Gastroenterol. 2019;25(35):5376-5387.
Crippa S, Partelli S, Belfiori G, et al. Management of neuroendocrine carcinomas of the pancreas (WHO G3): a tailored approach between proliferation and morphology. World J Gastroenterol. 2016;22(45):9944-9953.
Pellat A, Wislez M, Svrcek M, Hammel P, Afchain P, Andre T. Therapeutic management of poorly differentiated neuroendocrine lung tumors and neuroendocrine carcinomas of the digestive system. Bull Cancer. 2016;103(10):880-895.
Strosberg JR, Coppola D, Klimstra DS, et al. The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas. Pancreas. 2010;39(6):799-800.
Rindi G, Klimstra DS, Abedi-Ardekani B, et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol. 2018;31(12):1770-1786.
Basturk O, Yang Z, Tang LH, et al. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms. Am J Surg Pathol. 2015;39(5):683-690.
Velayoudom-Cephise FL, Duvillard P, Foucan L, et al. Are G3 ENETS neuroendocrine neoplasms heterogeneous?Endocr Relat Cancer. 2013;20(5):649-657.
Cao Y, Ma Y, Yu J, et al. Favorable response to immunotherapy in a pancreatic neuroendocrine tumor with temozolomide-induced high tumor mutational burden. Cancer Commun (Lond). 2020;40(12):746-751.
Tang LH, Basturk O, Sue JJ, Klimstra DS. A practical approach to the classification of WHO grade 3 (G3) well-differentiated neuroendocrine tumor (WD-NET) and poorly differentiated neuroendocrine carcinoma (PD-NEC) of the pancreas. Am J Surg Pathol. 2016;40(9):1192-1202.
Jackson AS, Rosenthal A, Cattoni M, et al. Staging system for neuroendocrine tumors of the lung needs to incorporate histologic grade. Ann Thorac Surg. 2020;109(4):1009-1018.